Opinion|Videos|September 27, 2024
Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5
Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please comment on the clinical trials evaluating combination strategies with bispecifics:
- Talquetamab
- RedirecTT-1
- Elranatamab
- MagnetisMM-30
- MagnetisMM-5
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
5